This article is more than 5 years old. Information may no longer be current.
BLOG: Approval of intracorneal inlays is good for everyone
In a nearly split decision by the U.S. Food and Drug Administration’s Ophthalmic Devices Panel on Friday, June 6, the Acufocus Kamra inlay was recommended for approval. This inlay, made of an opaque, fenestrated polyvinylidene, uses small-aperture optics — the pinhole effect — to assist near vision in implanted patients.
John A. Hovanesian
The Kamra inlay, which is implanted in one eye, met its primary endpoint of achieving uncorrected near acuity of 20/40 or better in nearly 85% of eyes at 12 months. Similar results have been seen with other inlays, such as the ReVision Optics Raindrop and Presbia’s Flexivue inlay, both also undergoing clinical trials prior to approval.
For three reasons, corneal inlays are a great, new modality of vision correction that will undoubtedly bring excitement back to keratorefractive surgery.
Read Hovanesian's full blog entry here.